Skip to main content

Table 4 Baseline characteristics of hypophosphatemic and non-hypophosphatemic patients

From: Effect of ferric carboxymaltose on serum phosphate and C-terminal FGF23 levels in non-dialysis chronic kidney disease patients: post-hoc analysis of a prospective study

 

Hypophosphatemic

Non-hypophosphatemic

p-value

 

(n = 35)

(n = 12)

 

Age(years)

72.3(11.2)

72.5(13.5)

ns

Serum creatinine, mg/dL

2.5(1)

2.7(0.7)

ns

eGFR, ml/min/1.73 m2

26.6(10.4)

24.6(10.4)

ns

Haemoglobin, g/dL

10(0.6)

10(0.8)

ns

Ferritin, ng/mL

64.1(58.3)

78.5(72.2)

ns

Transferrin saturation, %

14.6(6.4)

14.6(6.7)

ns

FCM, dosage(mg)

966.4(77.9)

987(31.6)

ns

Use of phosphate binders, n(%)

3(8.5)

1(8.3)

ns

Use of active vitamin D, n(%)

14(40)

4(33.3)

ns

Calcium, mg/dL

9.3(0.4)

9.3(0.6)

ns

Phosphate, mg/dL

4.1(0.8)

4.5(0.7)

ns

PTH, pg/mL

147.8(31.6-600)

84(2.5-404.9)

ns

25-hydroxyvitamin D, ng/mL

12.5(6)

13.8(8.5)

ns

1,25 dihydroxyvitamin D, pg/mL

10.3(4)

8.55(2)

ns

Fibroblast growth factor 23, RU/mL

437.5(44.9-2415)

844.1(148.4-4079.2)

ns